Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Top Cited Papers
- 20 July 2020
- journal article
- research article
- Published by Elsevier
- Vol. 396 (10249) , 479-488
- https://doi.org/10.1016/s0140-6736(20)31605-6
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2Emerging Microbes & Infections, 2020
- Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus FusionCell, 2019
- Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trialPublished by Elsevier ,2016
- Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in ChinaJournal of Medical Virology, 2012
- International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsVaccine, 2011
- The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccinesJournal of Medical Virology, 2010
- Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan AfricaJournal of Clinical Microbiology, 2006
- Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy VectorsJournal of Clinical Microbiology, 2003